| Year |
Citation |
Score |
| 2024 |
Pandey G, Mazzacurati L, Rowsell TM, Horvat NP, Amin NE, Zhang G, Akuffo AA, Colin-Leitzinger CM, Haura EB, Kuykendall AT, Zhang L, Epling-Burnette PK, Reuther GW. SHP2 inhibition displays efficacy as a monotherapy and in combination with JAK2 inhibition in preclinical models of myeloproliferative neoplasms. American Journal of Hematology. PMID 38440831 DOI: 10.1002/ajh.27282 |
0.414 |
|
| 2022 |
Pandey G, Kuykendall AT, Reuther GW. JAK2 inhibitor persistence in MPN: uncovering a central role of ERK activation. Blood Cancer Journal. 12: 13. PMID 35082276 DOI: 10.1038/s41408-022-00609-5 |
0.411 |
|
| 2020 |
Sharma V, Wright KL, Epling-Burnette PK, Reuther GW. Metabolic Vulnerabilities and Epigenetic Dysregulation in Myeloproliferative Neoplasms. Frontiers in Immunology. 11: 604142. PMID 33329600 DOI: 10.3389/fimmu.2020.604142 |
0.304 |
|
| 2020 |
Fang B, Izumi V, Rix LLR, Welsh E, Pike I, Reuther GW, Haura EB, Rix U, Koomen JM. Lowering Sample Requirements to Study Tyrosine Kinase Signaling using Phosphoproteomics with the TMT Calibrator Approach. Proteomics. e2000116. PMID 32865326 DOI: 10.1002/Pmic.202000116 |
0.349 |
|
| 2020 |
Kuykendall AT, Horvat NP, Pandey G, Komrokji R, Reuther GW. Finding a Jill for JAK: Assessing Past, Present, and Future JAK Inhibitor Combination Approaches in Myelofibrosis. Cancers. 12. PMID 32823910 DOI: 10.3390/Cancers12082278 |
0.418 |
|
| 2019 |
Yue L, Sharma V, Horvat NP, Akuffo AA, Beatty MS, Murdun C, Colin C, Billington J, Goodheart WE, Sahakian E, Zhang L, Powers JJ, Amin NE, Lambert-Showers QT, Darville LN, ... ... Reuther G, et al. HDAC11 Deficiency or Inhibition Disrupts Oncogene-Induced Stress Hematopoiesis in Myeloproliferative Neoplasms. Blood. PMID 31750881 DOI: 10.1182/Blood.2019895326 |
0.415 |
|
| 2019 |
Mazzacurati L, Collins RJ, Pandey G, Lambert-Showers QT, Amin NE, Zhang L, Stubbs MC, Epling-Burnette PK, Koblish HK, Reuther GW. The pan-PIM inhibitor INCB053914 displays potent synergy in combination with ruxolitinib in models of MPN. Blood Advances. 3: 3503-3514. PMID 31725895 DOI: 10.1182/Bloodadvances.2019000260 |
0.494 |
|
| 2019 |
Pandey G, Horvat N, Amin NE, Akuffo AA, Colin C, Epling-Burnette PK, Reuther GW. RMC-4550, an Allosteric Inhibitor of SHP2, Displays Therapeutic Efficacy in Pre-Clinical Models of Myeloproliferative Neoplasms Blood. 134: 4198-4198. DOI: 10.1182/Blood-2019-128937 |
0.546 |
|
| 2019 |
Letson C, Vedder A, Quintana A, Liu P, Reid B, Balasis ME, Newman H, Kruer T, Almada LL, Zhang G, Fernandez-Zapico M, Patnaik MM, Lancet JE, Komrokji RS, Epling-Burnette P, ... ... Reuther GW, et al. Bromodomain and Extra Terminal Domain (BET) Inhibitors Sensitize Chronic Myelomonocytic Leukemia (CMML) to PIM Inhibition Via Downregulation of Mir-33a Blood. 134: 4220-4220. DOI: 10.1182/Blood-2019-128165 |
0.404 |
|
| 2019 |
Sharma V, Yue L, Horvat NP, Christodoulidou A, Akuffo AA, Beatty M, Murdun C, Billington J, Goodheart WE, Sahakian E, Zhang L, Powers JJ, Amin NE, Lambert-Showers QT, Darville L, ... ... Reuther GW, et al. Selective Targeting of Histone Deacetylase 11 Disables Metabolism of Myeloproliferative Neoplasms Blood. 134: 474-474. DOI: 10.1182/Blood-2019-127235 |
0.403 |
|
| 2018 |
Koblish H, Li YL, Shin N, Hall L, Wang Q, Wang K, Covington M, Marando C, Bowman K, Boer J, Burke K, Wynn R, Margulis A, Reuther GW, Lambert QT, et al. Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignancies. Plos One. 13: e0199108. PMID 29927999 DOI: 10.1371/Journal.Pone.0199108 |
0.491 |
|
| 2018 |
Pandey G, Zhang G, Amin N, Mazzacurati L, Haura EB, Reuther GW. The Persistent Survival of MPN Cells to JAK2 Inhibition Is Dependent on SHP2 Activity, Which May Provide a Therapeutic Target to Enhance Current Anti-MPN Therapies Blood. 132: 3064-3064. DOI: 10.1182/Blood-2018-99-118641 |
0.554 |
|
| 2017 |
Ember SW, Lambert QT, Berndt N, Gunawan S, Ayaz M, Tauro M, Zhu JY, Cranfill PJ, Greninger P, Lynch CC, Benes CH, Lawrence HR, Reuther GW, Lawrence NJ, Schonbrunn E. Potent dual BET bromodomain-kinase inhibitors as value added multi-targeted chemical probes and cancer therapeutics. Molecular Cancer Therapeutics. PMID 28336808 DOI: 10.1158/1535-7163.Mct-16-0568-T |
0.431 |
|
| 2016 |
Reuther GW. Myeloproliferative Neoplasms: Molecular Drivers and Therapeutics. Progress in Molecular Biology and Translational Science. 144: 437-484. PMID 27865464 DOI: 10.1016/bs.pmbts.2016.09.004 |
0.363 |
|
| 2016 |
Basiorka AA, McGraw KL, De Ceuninck L, Griner LN, Zhang L, Clark JA, Caceres G, Sokol L, Komrokji RS, Reuther GW, Wei S, Tavernier J, List AF. Lenalidomide Stabilizes the Erythropoietin Receptor by Inhibiting the E3 Ubiquitin Ligase RNF41. Cancer Research. PMID 27197154 DOI: 10.1158/0008-5472.Can-15-1756 |
0.782 |
|
| 2015 |
Mazzacurati L, Lambert QT, Pradhan A, Griner LN, Huszar D, Reuther GW. The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells. Oncotarget. PMID 26472029 DOI: 10.18632/Oncotarget.5653 |
0.79 |
|
| 2015 |
Lambert QT, Ember SW, Ayaz M, Lawrence HR, Berndt N, Gunawan S, Lawrence NJ, Schönbrunn E, Reuther GW. Single Molecule Dual JAK2-BET Inhibition As an MPN Therapeutic Blood. 126: 2826-2826. DOI: 10.1182/Blood.V126.23.2826.2826 |
0.457 |
|
| 2015 |
Gunawan S, Muhammad A, Ember SWJ, Zhu J, Jacobsen RA, Berndt N, Lambert QT, Reuther GW, Lawrence HR, Schonbrunn E, Lawrence NJ. Abstract 3643: Targeting the acetyl-lysine binding site of BRD4 with dual nanomolar BET-JAK2 inhibitors: A new anticancer therapeutic strategy Cancer Research. 75: 3643-3643. DOI: 10.1158/1538-7445.Am2015-3643 |
0.397 |
|
| 2014 |
Lambert QT, Pradhan A, Reuther GW. Pims: Potential Therapeutic Targets for Myeloproliferative Neoplasms Blood. 124: 4575-4575. DOI: 10.1182/Blood.V124.21.4575.4575 |
0.561 |
|
| 2013 |
Griner LN, McGraw KL, Johnson JO, List AF, Reuther GW. JAK2-V617F-mediated signalling is dependent on lipid rafts and statins inhibit JAK2-V617F-dependent cell growth. British Journal of Haematology. 160: 177-87. PMID 23157224 DOI: 10.1111/Bjh.12103 |
0.8 |
|
| 2012 |
Roll JD, Reuther GW. ALK-activating homologous mutations in LTK induce cellular transformation. Plos One. 7: e31733. PMID 22347506 DOI: 10.1371/Journal.Pone.0031733 |
0.573 |
|
| 2011 |
Lambert QT, Pradhan A, Roll JD, Reuther GW. Mutations in the transmembrane and juxtamembrane domains enhance IL27R transforming activity. The Biochemical Journal. 438: 155-64. PMID 21631431 DOI: 10.1042/Bj20110351 |
0.48 |
|
| 2011 |
Griner LN, McGraw KL, Johnson JO, List AF, Reuther GW. A Mechanistic Rationale for the Use of Statins to Enhance JAK Inhibitor Therapy in MPNs Blood. 118: 2816-2816. DOI: 10.1182/Blood.V118.21.2816.2816 |
0.797 |
|
| 2010 |
Griner LN, Reuther GW. Aggressive myeloid leukemia formation is directed by the Musashi 2/Numb pathway. Cancer Biology & Therapy. 10: 979-82. PMID 21084860 DOI: 10.4161/Cbt.10.10.14010 |
0.766 |
|
| 2010 |
Gordon GM, Lambert QT, Daniel KG, Reuther GW. Transforming JAK1 mutations exhibit differential signalling, FERM domain requirements and growth responses to interferon-γ. The Biochemical Journal. 432: 255-65. PMID 20868368 DOI: 10.1042/Bj20100774 |
0.421 |
|
| 2010 |
Majumder A, Govindasamy L, Magis A, Kiss R, Polgár T, Baskin R, Allan RW, Agbandje-McKenna M, Reuther GW, Keseru GM, Bisht KS, Sayeski PP. Structure-function correlation of G6, a novel small molecule inhibitor of Jak2: indispensability of the stilbenoid core. The Journal of Biological Chemistry. 285: 31399-407. PMID 20667821 DOI: 10.1074/Jbc.M110.168211 |
0.37 |
|
| 2010 |
Rao R, Nalluri S, Fiskus W, Balusu R, Joshi A, Mudunuru U, Buckley KM, Robbins K, Ustun C, Reuther GW, Bhalla KN. Heat shock protein 90 inhibition depletes TrkA levels and signaling in human acute leukemia cells. Molecular Cancer Therapeutics. 9: 2232-42. PMID 20663926 DOI: 10.1158/1535-7163.Mct-10-0336 |
0.434 |
|
| 2010 |
Pradhan A, Lambert QT, Griner LN, Reuther GW. Activation of JAK2-V617F by components of heterodimeric cytokine receptors. The Journal of Biological Chemistry. 285: 16651-63. PMID 20363735 DOI: 10.1074/Jbc.M109.071191 |
0.797 |
|
| 2010 |
Griner LN, McGraw KL, Johnson JO, List AF, Reuther GW. Requirement of Lipid Raft Integrity for Signaling by JAK2-V617F Blood. 116: 4191-4191. DOI: 10.1182/Blood.V116.21.4191.4191 |
0.806 |
|
| 2009 |
Pradhan AR, Lambert QT, Griner LN, Reuther GW. Activation of JAK2-V617F by Heterodimeric Receptor Components. Blood. 114: 2955-2955. DOI: 10.1182/Blood.V114.22.2955.2955 |
0.786 |
|
| 2008 |
Cha JY, Lambert QT, Reuther GW, Der CJ. Involvement of fibroblast growth factor receptor 2 isoform switching in mammary oncogenesis. Molecular Cancer Research : McR. 6: 435-45. PMID 18337450 DOI: 10.1158/1541-7786.Mcr-07-0187 |
0.666 |
|
| 2008 |
Gilkes DM, Pan Y, Coppola D, Yeatman T, Reuther GW, Chen J. Regulation of MDMX expression by mitogenic signaling. Molecular and Cellular Biology. 28: 1999-2010. PMID 18172009 DOI: 10.1128/Mcb.01633-07 |
0.363 |
|
| 2008 |
Pradhan AR, Lambert Q, Reuther GW. A Component of a Heterodimeric Receptor Can Functionally Replace a Homodimeric Receptor in Supporting the Activation and Transforming Activity of JAK2-V617F Blood. 112: 3732-3732. DOI: 10.1182/Blood.V112.11.3732.3732 |
0.558 |
|
| 2007 |
Pradhan A, Lambert QT, Reuther GW. Transformation of hematopoietic cells and activation of JAK2-V617F by IL-27R, a component of a heterodimeric type I cytokine receptor. Proceedings of the National Academy of Sciences of the United States of America. 104: 18502-7. PMID 18003935 DOI: 10.1073/Pnas.0702388104 |
0.404 |
|
| 2007 |
Ren Y, Chen Z, Chen L, Woods NT, Reuther GW, Cheng JQ, Wang HG, Wu J. Shp2E76K mutant confers cytokine-independent survival of TF-1 myeloid cells by up-regulating Bcl-XL. The Journal of Biological Chemistry. 282: 36463-73. PMID 17942397 DOI: 10.1074/Jbc.M705789200 |
0.447 |
|
| 2006 |
Lambert QT, Reuther GW. Activation of Ras proteins by Ras guanine nucleotide releasing protein family members. Methods in Enzymology. 407: 82-98. PMID 16757316 DOI: 10.1016/S0076-6879(05)07008-4 |
0.407 |
|
| 2006 |
Pradhan A, Lambert Q, Reuther G. A Functional Screen of Genes Expressed in AML Patients Identifies Novel Transforming Properties of IL27R. Blood. 108: 1454-1454. DOI: 10.1182/Blood.V108.11.1454.1454 |
0.554 |
|
| 2006 |
Li Z, Meyer J, Rhein M, Kustikova O, Rudolph C, Kamino K, Neumann T, Yang M, Wahlers A, Fehse B, Reuther GW, Schlegelberger B, Ganser A, Baum C. Leukemogenic Cascade Induced by a Constitutively Active Neurotrophin Receptor, ΔTrkA. Blood. 108: 1442-1442. DOI: 10.1182/blood.v108.11.1442.1442 |
0.456 |
|
| 2005 |
Kumaraswamy S, Lambert QT, Rocha K, Bali P, Fiskus W, Balasis M, Pranpat M, Boyapalle S, Hannah A, Reuther GW, Bhalla K. Treatment with the Heat Shock Protein (hsp) 90 Inhibitor17-Dimethylaminoethylamino-17-Demethoxygeldanamycin (DMAG) Abrogates the Levels and Activity of the Receptor Tyrosine Kinase TrkA in Acute Leukemia Cells. Blood. 106: 4401-4401. DOI: 10.1182/Blood.V106.11.4401.4401 |
0.487 |
|
| 2002 |
Lambert JM, Lambert QT, Reuther GW, Malliri A, Siderovski DP, Sondek J, Collard JG, Der CJ. Tiam1 mediates Ras activation of Rac by a PI(3)K-independent mechanism. Nature Cell Biology. 4: 621-5. PMID 12134164 DOI: 10.1038/Ncb833 |
0.661 |
|
| 2002 |
Reuther GW, Lambert QT, Rebhun JF, Caligiuri MA, Quilliam LA, Der CJ. RasGRP4 is a novel Ras activator isolated from acute myeloid leukemia. The Journal of Biological Chemistry. 277: 30508-14. PMID 11880369 DOI: 10.1074/Jbc.M111330200 |
0.547 |
|
| 2001 |
Reuther GW, Lambert QT, Booden MA, Wennerberg K, Becknell B, Marcucci G, Sondek J, Caligiuri MA, Der CJ. Leukemia-associated Rho Guanine Nucleotide Exchange Factor, a Dbl Family Protein Found Mutated in Leukemia, Causes Transformation by Activation of RhoA Journal of Biological Chemistry. 276: 27145-27151. PMID 11373293 DOI: 10.1074/Jbc.M103565200 |
0.617 |
|
| 2000 |
Reuther GW, Lambert QT, Caligiuri MA, Der CJ. Identification and characterization of an activating TrkA deletion mutation in acute myeloid leukemia. Molecular and Cellular Biology. 20: 8655-66. PMID 11073967 DOI: 10.1128/Mcb.20.23.8655-8666.2000 |
0.651 |
|
| 2000 |
Reuther GW, Buss JE, Quilliam LA, Clark GJ, Der CJ. Analysis of function and regulation of proteins that mediate signal transduction by use of lipid-modified plasma membrane-targeting sequences Methods in Enzymology. 327: 331-350. PMID 11044995 DOI: 10.1016/S0076-6879(00)27288-1 |
0.555 |
|
| 2000 |
Farwell DG, Shera KA, Koop JI, Bonnet GA, Matthews CP, Reuther GW, Coltrera MD, McDougall JK, Klingelhutz AJ. Genetic and epigenetic changes in human epithelial cells immortalized by telomerase. The American Journal of Pathology. 156: 1537-47. PMID 10793065 DOI: 10.1016/S0002-9440(10)65025-0 |
0.3 |
|
| 2000 |
Reuther GW, Der CJ. The Ras branch of small GTPases: Ras family members don't fall far from the tree. Current Opinion in Cell Biology. 12: 157-65. PMID 10712923 DOI: 10.1016/S0955-0674(99)00071-X |
0.403 |
|
| 2000 |
Quackenbush RC, Reuther GW, Miller JP, Courtney KD, Pear WS, Pendergast AM. Analysis of the biologic properties of p230 Bcr-Abl reveals unique and overlapping properties with the oncogenic p185 and p210 Bcr-Abl tyrosine kinases Blood. 95: 2913-2921. DOI: 10.1182/Blood.V95.9.2913.009K32_2913_2921 |
0.726 |
|
| 1998 |
Dai Z, Quackenbush RC, Courtney KD, Grove M, Cortez D, Reuther GW, Pendergast AM. Oncogenic Abl and Src tyrosine kinases elicit the ubiquitin-dependent degradation of target proteins through a Ras-independent pathway. Genes & Development. 12: 1415-24. PMID 9585502 DOI: 10.1101/Gad.12.10.1415 |
0.789 |
|
| 1998 |
Reuther JY, Reuther GW, Cortez D, Pendergast AM, Baldwin AS. A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation. Genes & Development. 12: 968-81. PMID 9531535 DOI: 10.1101/Gad.12.7.968 |
0.75 |
|
| 1997 |
Cortez D, Reuther G, Pendergast AM. The Bcr-Abl tyrosine kinase activates mitogenic signaling pathways and stimulates G1-to-S phase transition in hematopoietic cells. Oncogene. 15: 2333-42. PMID 9393877 DOI: 10.1038/Sj.Onc.1201400 |
0.785 |
|
| 1996 |
Reuther GW, Pendergast AM. The roles of 14-3-3 proteins in signal transduction. Vitamins and Hormones. 52: 149-75. PMID 8909160 DOI: 10.1016/S0083-6729(08)60410-0 |
0.642 |
|
| 1994 |
Reuther GW, Fu H, Cripe LD, Collier RJ, Pendergast AM. Association of the protein kinases c-Bcr and Bcr-Abl with proteins of the 14-3-3 family. Science (New York, N.Y.). 266: 129-33. PMID 7939633 DOI: 10.1126/Science.7939633 |
0.747 |
|
| Show low-probability matches. |
